Physician profile
Christopher Ferguson
NPI 1073068334
$481.16
in general payments reported to CMS, 2019-2025
11 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.24 · 2022: $71.25 · 2023: $133 · 2024: $123 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $121.81 | 2023 | |
| Corium, LLC | $102.45 | 2022-2025 | Azstarys |
| Phathom Pharmaceuticals, INC. | $79.20 | 2024 | Voquezna |
| Genentech USA, INC. | $45.57 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $30.75 | 2025 | Fanapt |
| Abbvie INC. | $24.76 | 2024 | |
| Vertical Pharmaceuticals, LLC | $20.04 | 2025 | Relexxii |
| Otsuka America Pharmaceutical, INC. | $18.56 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.00 | 2022 | |
| Hologic Sales and Service, LLC | $14.10 | 2021 | |
| Dynavax Technologies Corporation | $8.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.